Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 160; no. 4; pp. 1373 - 1383.e6
• Main Authors: Fahrmann, Johannes F., Schmidt, C. Max, Mao, Xiangying, Irajizad, Ehsan, Loftus, Maureen, Zhang, Jinming, Patel, Nikul, Vykoukal, Jody, Dennison, Jennifer B., Long, James P., Do, Kim-Anh, Zhang, Jianjun, Chabot, John A., Kluger, Michael D., Kastrinos, Fay, Brais, Lauren, Babic, Ana, Jajoo, Kunal, Lee, Linda S., Clancy, Thomas E., Ng, Kimmie, Bullock, Andrea, Genkinger, Jeanine, Yip-Schneider, Michele T., Maitra, Anirban, Wolpin, Brian M., Hanash, Samir
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2021
• Subjects: Aged; Biomarker; CA-19-9 Antigen - blood; Detection; Diagnosis, Differential; Early Detection of Cancer - methods; Feasibility Studies; Female; Healthy Volunteers; Humans; Liquid Biopsy - methods; Male; Mass Screening - methods; Middle Aged; Pancreatic Cancer; Pancreatic Cyst - blood; Pancreatic Cyst - diagnosis; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - diagnosis; Pancreatitis, Chronic - blood; Pancreatitis, Chronic - diagnosis; Sensitivity and Specificity; United States; United States; Biomarker; CI; Lung; ROC; IPMN; Pancreatic Cancer; CP; PLCO; AUC; PDAC; CUMC; Detection; DFCI/BWH; ELISA

There is substantial interest in liquid biopsy approaches for cancer early detection among subjects at risk, using multi-marker panels. CA19-9 is an established circulating biomarker for pancreatic cancer; however, its relevance for pancreatic cancer early detection or for monitoring subjects at ris...